Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/187148
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Preparation of titanocene-gold compounds based on highly active gold(I)-N-heterocyclic carbene anticancer agents: Preliminary in vitro studies in renal and prostate cancer cell lines |
Autor: | Curado, Natalia CSIC ORCID; Giménez, Nora; Miachin, Kirill; Aliaga-Lavrijsen, Mélanie CSIC; Cornejo, Mike A.; Jarzecki, Andrzej A.; Contel, María | Palabras clave: | Heterometallic compounds N-heterocyclic carbenes Prostate cancer Renal cancer Titanocene-gold |
Fecha de publicación: | 2019 | Editor: | Wiley-VCH | Citación: | ChemMedChem 14(11): 1086-1095 (2019) | Resumen: | Heterometallic titanocene-based compounds containing gold(I)-phosphane fragments have been extremely successful against renal cancer in vitro and in vivo. The exchange of phosphane by N-heterocyclic carbene ligands to improve or modulate their pharmacological profile afforded bimetallic complexes effective against prostate cancer, but less effective against renal cancer in vitro. Herein we report the synthesis of new bimetallic Ti-Au compounds by the incorporation of two previously reported highly active gold(I)-N-heterocyclic carbene fragments derived from 4,5-diarylimidazoles. The two new compounds [(η5 -C5 H5 )2 TiMe(μ-mba)Au(NHC)] (where NHC=1,3-dibenzyl-4,5-diphenylimidazol-2-ylidene, NHC-Bn 2 a; or 1,3-diethyl-4,5-diphenylimidazol-2-ylidene, NHC-Et 2 b) with the dual linker (-OC(O)-p-C6 H4 -S-) containing both a carboxylate and a thiolate group were evaluated in vitro against renal and prostate cancer cell lines. The compounds were found to be more cytotoxic than previously described Ti-Au compounds containing non-optimized gold(I)-N-heterocyclic fragments. We present studies to evaluate their effects on cell death pathways, migration, inhibition of thioredoxin reductase (TrxR) and vascular endothelial growth factor (VEGF) in the PC3 prostate cancer cell line. The results show that the incorporation of a second metallic fragment such as titanocene into biologically active gold(I) compounds improves their pharmacological profile. | Versión del editor: | https://doi.org/10.1002/cmdc.201800796 | URI: | http://hdl.handle.net/10261/187148 | DOI: | 10.1002/cmdc.201800796 | ISSN: | 1860-7179 | E-ISSN: | 1860-7187 |
Aparece en las colecciones: | (ISQCH) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 59,24 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
8
checked on 20-abr-2024
SCOPUSTM
Citations
27
checked on 17-abr-2024
WEB OF SCIENCETM
Citations
25
checked on 24-feb-2024
Page view(s)
165
checked on 23-abr-2024
Download(s)
21
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.